RealCold, a rapidly growing cold chain solutions provider, announced the acquisition of SCL Cold Chain, a Dallas-based logistics company specializing in temperature-controlled supply chains for pharmaceuticals, medical devices, wine, and specialty foods. The transaction marks RealCold’s entry into chain-of-custody pharmaceutical logistics while expanding the range of services available across its national cold chain network.
Founded in 2022, RealCold has focused on delivering customized cold chain solutions for food producers, retailers, and distributors. Through the acquisition, the company adds SCL’s pharmaceutical logistics expertise, including continuous temperature monitoring, FDA-registered facilities, and end-to-end cold chain custody capabilities. The deal also brings CEIV Pharma certification to RealCold’s platform, complementing the company’s existing FSMA and SQF certifications across more than 61 million cubic feet of temperature-controlled storage space and over 180,000 pallet positions nationwide.
The companies noted that the transaction aligns organizations with similar customer-focused operating philosophies. RealCold gains specialized expertise in pharmaceutical cold chain management, while SCL receives access to a larger national infrastructure and resources to expand its services beyond the Dallas-Fort Worth market.
RealCold said the combined platform will provide pharmaceutical manufacturers with greater access to compliant, temperature-controlled logistics services for medications, biologics, vaccines, and clinical trial materials. Food, produce, wine, and specialty product customers are also expected to benefit from expanded warehousing capacity, fulfillment services, and logistics capabilities.
Following the acquisition, SCL Cold Chain will continue operating under its existing corporate identity as part of the RealCold organization.
KEY QUOTES:
“From our first conversations with the SCL team, it was clear that they had accomplished something exceptional: they built genuine expertise in a highly specialized and demanding vertical while maintaining exactly the customer-centric mindset that RealCold is known for. This transaction goes beyond an acquisition of capabilities; it is an alignment of values, culture, and vision. With RealCold’s capital, national network, and platform, we are positioned to scale SCL’s capabilities to serve the world’s leading pharmaceutical companies in ways that were not previously possible.”
Keith Goldsmith, CEO, RealCold
“This is a transformative moment for SCL and for our customers. We have spent considerable time building something differentiated in the pharmaceutical cold chain, a service that merges operational rigor, an experienced team, and above all, the trust of our clients. The opportunity to bring those capabilities to a national audience through RealCold’s platform is extraordinary. With the additional resources and reach that RealCold provides, we can significantly expand our customer base. The demand for compliant, end-to-end pharma cold chain is enormous, and we are now positioned to meet it at scale.”
Bryan Severin, President, SCL Cold Chain
